Outlook Therapeutics Interest Expense 2011-2026 | OTLK

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Outlook Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-1.49 M	-936 K	1.76 M	3.47 M	3.89 M	5.63 M	1.47 M	2.3 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
5.63 M	-1.49 M	2.01 M

Quarterly Interest Expense Outlook Therapeutics

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-49.4 K	-18.5 K	48.9 K	-	405 K	-3.08 M	189 K	-	303	188 K	-2.45 M	-1.13 M	-357 K	-418 K	-352 K	-667 K	-257 K	250 K	160 K	-1.74 M	444 K	696 K	598 K	3.26 M	1.08 M	598 K	1.12 M	2.79 M	1.15 M	1.12 M	718 K	3.48 M	1.75 M	718 K	489 K	1.24 M	299 K	387 K	399 K	1.62 M	555 K	706 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
3.48 M	-3.08 M	398 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Esperion Therapeutics ESPR	3.49 M	$ 3.13	0.55 %	$ 651 M	USA
Exelixis EXEL	-198 K	$ 48.2	8.51 %	$ 13.1 B	USA
Fortress Biotech FBIO	17.6 M	$ 2.53	2.85 %	$ 70.6 M	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Galapagos NV GLPG	1.03 M	$ 28.81	1.48 %	$ 2.69 B	Belgium
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Genprex GNPX	38 K	$ 0.91	2.24 %	$ 849 K	USA
InflaRx N.V. IFRX	2.69 K	$ 2.51	27.16 %	$ 152 M	Germany
Ionis Pharmaceuticals IONS	17.3 M	$ 77.0	2.33 %	$ 12.3 B	USA
BioNTech SE BNTX	14.2 M	$ 94.64	-0.9 %	$ 27.2 B	Germany
Kymera Therapeutics KYMR	38 M	$ 85.79	3.72 %	$ 7.25 B	USA
Ligand Pharmaceuticals Incorporated LGND	-54.9 M	$ 231.58	-0.31 %	$ 4.24 B	USA
INmune Bio INMB	2.28 M	$ 1.54	-	$ 38.1 M	USA
Liquidia Corporation LQDA	2.34 M	$ 41.64	3.75 %	$ 3.58 B	USA
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.58	1.03 %	$ 3.74 B	USA
Mirum Pharmaceuticals MIRM	2.37 M	$ 107.36	1.46 %	$ 5.39 B	USA
MannKind Corporation MNKD	-1.01 M	$ 3.61	26.17 %	$ 1.1 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.46	-1.14 %	$ 5.7 M	Israel
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 24.0	2.46 %	$ 3.05 B	USA
Nanobiotix S.A. NBTX	-4.68 M	$ 41.6	19.64 %	$ 286 B	France
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA